Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.
Condition or disease
Drug: Difluprednate Ophthalmic Emulsion
The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion (DFBA) in patients with endogenous anterior uveitis, in comparison with 0.1% betamethasone sodium phosphate ophthalmic solution (BP).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients diagnosed with endogenous anterior uveitis or panuveitis
Patients with 10 - 49 anterior chamber cells within one field of the anterior chamber as observed by slit lamp microscopy (criterion for rating of signs 2 or 3)
Patients aged ‰1425 years (on the day of obtaining informed consent) who were able to accurately express their own symptoms
Patients provided written informed consent prior to initiation of the study
Patients who did not meet all of the above inclusion criteria
Patients received systemic administration of any corticosteroid or immunosuppressive drug within the past 1 week prior to instillation of the investigational product
Patients received topical injection of any corticosteroid in eyes prior to instillation of the investigational product (Solution formulation: within the past 1 week, depot: within the past 2 weeks)
Patients received systemic administration of any non-steroidal anti-inflammatory drug or antiphlogistic enzyme within the past 3 days prior to instillation of the investigational product
Patients received instillation of any corticosteroid, non-steroidal anti-inflammatory drug or antiphlogistic enzyme within 12 hours prior to instillation of the investigational product
Patients with glaucoma or ocular hypertension
Patients with corneal abrasion or ulcer
Patients with any confirmed or suspected viral, bacterial or fungal keratoconjunctival disease
Patients with allergy to similar drugs such as other corticosteroids
Patients requiring use of contact lens during the study period
Women who are or might be pregnant, or lactating women
Patients participating in another clinical study within the past 3 months before initiation of the present study